Corrie Lipids Digital Health Program for Cardiovascular Risk

Overseen By Francoise Marvel, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Johns Hopkins University

Must be taking: Lipid-lowering therapy

Disqualifiers: Malignancy, Pregnancy, Impairments, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

1000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to test the Corrie Lipids Digital Health Program, which helps people manage high cholesterol, a risk factor for heart disease. The program includes a smartphone app for patients, coaching for doctors, and easy integration into medical practices. Researchers aim to determine if it helps people reach cholesterol goals and improves how doctors prescribe and monitor treatments. Individuals with high cholesterol, a smartphone, a history of heart disease or diabetes, and who are under a doctor’s care for cholesterol management might be a good fit. As an unphased study, this trial offers a unique opportunity to contribute to innovative research that could enhance cholesterol management for many.

What prior data suggests that the Corrie Lipids Digital Health Program is safe?

Research has shown that the Corrie Lipids Digital Health Program is designed to manage LDL-C, a type of bad cholesterol, and reduce the risk of heart disease. While specific safety data from past studies is not available in the provided sources, this program functions as a digital health tool. It combines a smartphone app with support and education from healthcare professionals.

Digital health tools like this are generally safe because they do not involve new medications or medical procedures. Instead, they emphasize education and behavior change, which are typically safe. The trial's "Not Applicable" phase label suggests very low safety risks, as it does not involve testing a new drug or invasive treatment. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the Corrie Lipids Digital Health Program because it offers a fresh approach to managing cardiovascular risk through a digital platform. Unlike traditional treatments that might rely on medication or in-person consultations, this program uses technology to provide personalized lipid management and education. This innovative method allows for continuous monitoring and real-time feedback, potentially improving patient engagement and outcomes in a way that standard care cannot.

What evidence suggests that the Corrie Lipids Digital Health Program is effective for cardiovascular risk management?

Research has shown that digital health tools, such as the Corrie Lipids Program studied in this trial, can help lower LDL cholesterol, often called "bad" cholesterol, and improve heart health in people with heart disease. This program uses a smartphone app to educate and engage patients in managing their cholesterol levels. Studies have found that these digital tools can enhance heart health by helping patients adhere to their treatment plans and track their progress. The Corrie Lipids Program is also designed to integrate smoothly with healthcare providers, potentially offering more consistent support. Overall, early results suggest this approach can fill gaps in care and improve heart health. ^{1 3 6 7 8}

Who Is on the Research Team?

Stacey Schott, MD, MPH

Principal Investigator

Johns Hopkins University

Are You a Good Fit for This Trial?

Inclusion Criteria

I am 18 years old or older.

I have at least one major heart or cholesterol risk factor.

Uncontrolled LDL-C per AHA/ACC guidelines

Exclusion Criteria

Motor, cognitive, auditory, or visual impairment limiting technology use

Does not speak English

I have not had any cancer (except certain skin, cervical, or breast cancers) in the past 5 years.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants engage with the Corrie Lipids Program, a digital health initiative for lipid management

6 months

Ongoing app engagement and clinician interactions

Follow-up

Participants are monitored for LDL-C goal attainment and app engagement

6 months

Regular digital check-ins and assessments

Extended Follow-up

Continued monitoring of LDL-C levels and program adoption

6 months

What Are the Treatments Tested in This Trial?

Interventions

• Corrie Lipids Digital Health Program

How Is the Trial Designed?

Group I: Corrie Lipids Program Experimental Treatment 1 Intervention

Multicomponent digital health lipid management and education program

Who Is Running the Clinical Trial?

Johns Hopkins University

Lead Sponsor

Trials

2,366

Recruited

15,160,000+

Amgen

Industry Sponsor

Trials

1,508

Recruited

1,433,000+

Founded

1980

Headquarters

Thousand Oaks, USA

Known For

Human Therapeutics

Top Products

Enbrel, Prolia, Neulasta, Otezla

Robert A. Bradway

Amgen

Chief Executive Officer since 2012

MBA from Harvard Business School

Paul Burton

Amgen

Chief Medical Officer since 2023

MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London

NewAmsterdam Pharma

Industry Sponsor

Trials

17

Recruited

13,900+

Citations

1.

pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/41935556/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=18y2KI_P1NiR7OoLaAmfNFisk3EmOVjA0uhoixnZF_cUGPgI6Z&fc=None&ff=20260412074058&v=2.19.0.post6+133c1fe

Rationale and design of the Corrie Lipids Program

Rationale and design of the Corrie Lipids Program: Impact of a digital health-enabled implementation initiative to improve lipid management.

2.

thelancet.com

thelancet.com/journals/eclinm/article/PIIS2589-5370(26)00133-1/fulltext

Digital health interventions for lipid management in ...

Our findings suggest that digital health interventions can support LDL-c reduction and lipid control in patients with ASCVD. Multi-component interventions were ...

3.

corriehealth.com

corriehealth.com/corrielipids

Corrie Lipids

By focusing on education, engagement and streamlined care, we aim to tackle gaps in care head-on to improve lipids and cardiovascular outcomes.

4.

academic.oup.com

academic.oup.com/ehjacc/advance-article/doi/10.1093/ehjacc/zuaf137/8305357

COR Lipid Registry: the effectiveness of the strike early and ...

According to real-world data, only up to 20% of patients with atherosclerotic cardiovascular disease (ASCVD) are below the recommended ...

5.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC12287401/

Effectiveness of digital healthcare to improve clinical ... - PMC

This study analyzed 16,797 CAD patients enrolled in the HeartMed Digital Management System (June 2018–September 2022), comparing outcomes ...

6.

ctv.veeva.com

ctv.veeva.com/study/impact-of-the-corrie-lipids-digital-health-program-on-lipid-optimization

Impact of the Corrie Lipids Digital Health Program on Lipid ...

Researchers plan to assess this multicenter digital health initiative in approximately 1,000 adults with uncontrolled LDL-C and elevated ASCVD ...

7.

ahajournals.org

ahajournals.org/doi/10.1161/CIRCOUTCOMES.124.010884?doi=10.1161/CIRCOUTCOMES.124.010884

Clinician Decision Support Tools: Advances in Lipid ...

According to the American Heart Association 2024 Heart Disease and Stroke Statistics, cardiovascular disease remains the leading cause of ...

8.

jacc.org

jacc.org/doi/10.1016/j.jacc.2025.11.016

2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ ...

Most reported parameters from advanced lipoprotein testing do not meaningfully reclassify or enable improved management of CVD risk beyond indices provided with ...